|
Hutchmed China Ltd on Monday said it has started the phase three part of a trial evaluating surufatinib and camrelizumab for the treatment of pancreatic cancer in China. The Hong Kong-based developer of treatments for cancer and immunological diseases said the trial is to evaluate the combination as a first-line treatment for metastatic pancreatic ductal adenocarcinoma, which is a highly aggressive form of cancer. Under 20% of metastatic pancreatic cancer patients survive for more than a year, according to a study in the World Journal of Gastrointestinal Oncology. The trial will compare surufatinib combined with camrelizumab, nab-paclitaxel and gemcitabine, to the current treatment of gemcitabine and nab-paclitaxel. Hutchmed said the first patient received the first dose on Tuesday last week. The company plans to enrol approximately 400 additional patients in the phase three part, following 62 in phase two. Shares in Hutchmed China rose 0.3% to 204.60 pence on Monday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
